Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth (Q39188198)

9 September 2017

Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth (English)

1 reference

9 September 2017

1 reference

1 reference

1 reference

1 reference

Liantao Li

8

0 references

author name string

Yuan Li

1

1 reference

9 September 2017

Baofu Zhang

2

1 reference

9 September 2017

Hongwei Zhang

3

1 reference

9 September 2017

Xiaoyu Zhu

4

1 reference

9 September 2017

Dongchuan Feng

5

1 reference

9 September 2017

Deyong Zhang

6

1 reference

9 September 2017

Baobiao Zhuo

7

1 reference

9 September 2017

Junnian Zheng

9

1 reference

9 September 2017

language of work or name

1 reference

27 February 2013

1 reference

Journal of Cancer Research and Clinical Oncology

9 September 2017

1 reference

9 September 2017

139

1 reference

9 September 2017

6

1 reference

9 September 2017

933-941

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-013-1406-4

9 September 2017

0 references

cites work

Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Development of treatment strategies for advanced neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Immunocombination therapy for high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

The MYCN oncoprotein as a drug development target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Oncolytic-adenovirus-expressed RNA interference for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Oncolytic adenovirus treatment of a patient with refractory neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Neuroblastoma as a neurobiological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Molecularly guided therapy of neuroblastoma: a review of different approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

The MYCN oncogene and differentiation in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

p53 determines multidrug sensitivity of childhood neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

Recent advances in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1406-4

A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy

21 January 2018

1 reference

12 December 2020

Oncolytic virotherapy for neuroblastoma

1 reference

12 December 2020

Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells.

1 reference

12 December 2020

Cancer-specific viruses and the development of ONYX-015

1 reference

12 December 2020

Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene

1 reference

12 December 2020

Cancer gene therapy with oncolytic adenoviruses.

1 reference

12 December 2020

Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines

1 reference

12 December 2020

Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification.

1 reference

12 December 2020

10.1007/S00432-013-1406-4

Identifiers

DOI

1 reference

9 September 2017

1 reference